Gossamer Bio, Inc.
Public company- Headquarters
- SAN DIEGO, California
- Ticker
- GOSS
- CIK
- 0001728117
WARN notices since 2024
1
First: Mar 16, 2026
Workers affected since 2024
65
Across 1 notice
Executive changes, last 12 months
1
1 appointment, 0 departures
Last event
Sep 16, 2026
Executive appointmentClass III director appointed: Gregory A. Ciongoli
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class III directorGregory A. Ciongoli | Sep 16, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
Class III director appointed: Gregory A. Ciongoli
Gregory A. Ciongoli was named Class III director of Gossamer Bio, Inc., effective September 16, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 16, 2026Role: Class III director
Last verified Nov 8, 2026